Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Citarinostat + Pomalidomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Citarinostat||ACY-241|CC-96241||HDAC Inhibitor 42||Citarinostat (ACY-241) selectively inhibits HDAC6, which potentially results in decreased tumor cell viability and reduced tumor growth, particularly in combination with other agents (PMID: 27926524, PMID: 28264055, PMID: 32394008).|
|Pomalidomide||Pomalyst||CC-4047||Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|